References
Ajello L: Soil as natural reservoir for human pathogenic fungi. Science 1956, 123: 876–879.
Cooke WB, Kabler P: Isolation of potentially pathogenic fungi from polluted water and sewage. Public Health Reports 1955, 70: 689–694.
Hung CC, Chang SC, Yang PC, Hsieh WC: Invasive pulmonary pseudallescheriasis with direct invasion of the thoracic spine in an immunocompetent patient. European Journal of Clinical Microbiology & Infectious Diseases 1994, 13: 749–751.
Travis LB, Roberts GD, Wilson WR: Clinical significance ofPseudallescheria boydii: a review of 10 years' experience. Mayo Clinic Proceedings 1985, 60: 531–537.
Lutwick LI, Galgiani JN, Johnson RH, Stevens DA: Visceral fungal infections due toPetriellidium boydii: (Allescheria boydii). In vitro drug susceptibility studies. American Journal of Medicine 1976, 61: 632–640.
Ruxin TA, Steck WD, Helm TN, Bergfeld WF, Bolwell BJ:Pseudallescheria boydii in an immunocompromised host. Successful treatment with débridement and itraconazole. Archives of Dermatology 1996, 132: 382–384.
Stolk-Engelaar MVM, Cox NJM: Successful treatment of pulmonary pseudallescheriasis with itraconazole. European Journal of Clinical Microbiology & Infectious Diseases 1993, 12: 142.
Goldberg SL, Geha DJ, Marshall WF, Inwards DJ, Hoagland HC: Successful treatment of simultaneous pulmonaryPseudallescheria boydii andAspergillus fumigatus infection with oral itraconazole. Clinical Infectious Diseases 1993, 16: 803–805.
Petranyi G, Meingassner JG, Mieth H: Antifungal activity of the allylamine derivate terbinafine in vitro. Antimicrobial Agents and Chemotherapy 1987, 31: 1365–1368.
Shadomy S, Espinell-Ingroff A, Gebhart RJ: In vitro studies with SF 86-327, a new orally active allylamine derivate. Sabouraudia 1985, 23: 125–132.
Galgiani JN, Stevens DA, Graybill JR, Stevens DL, Tillinghast AJ, Levine HB:Pseudallescheria boydii infections treated with ketoconazole. Chest 1984, 86: 219–224.
Walsh TJ, Peter J, McGough DA, Fothergill AW, Rinaldi MG, Pizzo PA: Activities of amphotericin B and antifungal azoles alone and in combination againstPseudallescheria boydii. Antimicrobial Agents and Chemotherapy 1995, 39: 1361–1364.
Villars VV, Jones TC: Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. British Journal of Dermatology 1992, 126, Supplement 39: 61–69.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Verweij, P.E., Cox, N.J.M. & Meis, J.F.G. Oral terbinafine for treatment of pulmonaryPseudallescheria boydii infection refractory to itraconazole therapy. Eur. J. Clin. Microbiol. Infect. Dis. 16, 26–28 (1997). https://doi.org/10.1007/BF01575117
Issue Date:
DOI: https://doi.org/10.1007/BF01575117